Abstract
Daptomycin has been approved and successfully launched for the treatment of complicated skin and skin-structure infections caused by gram-positive pathogens [1] and bacteremia and right-sided endocarditis due to Staphylococcus aureus, including strains that are resistant to methicillin or other antibiotics [2]. The development of the drug, however, was not straightforward; it involved a cast of characters, including scientists at Eli Lilly and at Cubist Pharmaceuticals. Of most importance, the development of daptomycin involved the tenacious leadership of Dr. Francis Tally. As a tribute to Dr. Tally, we attempt to reconstruct the path of daptomycin from the mountain to the clinic.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Bacterial Agents* / chemistry
-
Anti-Bacterial Agents* / pharmacology
-
Anti-Bacterial Agents* / therapeutic use
-
Bacteremia / drug therapy
-
Bacteremia / microbiology
-
Clinical Trials as Topic
-
Daptomycin* / chemistry
-
Daptomycin* / pharmacology
-
Daptomycin* / therapeutic use
-
Drug Approval
-
Drug Design
-
Drug Resistance, Bacterial*
-
Endocarditis, Bacterial / drug therapy
-
Endocarditis, Bacterial / microbiology
-
Gram-Positive Bacteria / drug effects*
-
Gram-Positive Bacterial Infections / drug therapy*
-
Gram-Positive Bacterial Infections / microbiology
-
Humans
-
Microbial Sensitivity Tests
-
Skin Diseases, Bacterial / drug therapy
-
Skin Diseases, Bacterial / microbiology
-
Soft Tissue Infections / drug therapy
-
Soft Tissue Infections / microbiology
-
Staphylococcus aureus / drug effects
Substances
-
Anti-Bacterial Agents
-
Daptomycin